scholarly journals Erecteur a dépression (Vacuum erection device): Mise au point

Andrologie ◽  
1999 ◽  
Vol 9 (1) ◽  
pp. 53-59
Author(s):  
D. Delavierre
Keyword(s):  
Vacuum Erection Device

Medical Management of Erectile Dysfunction

2018 ◽  
Author(s):  
Matthew G Cowper ◽  
Andrew T Gabrielson ◽  
Laith M Alzweri ◽  
Wayne J Hellstrom
Keyword(s):  
Erectile Dysfunction ◽  
Medical Management ◽  
Treatment Modalities ◽  
Pharmacologic Therapy ◽  
Intracavernosal Injection ◽  
Future Directions ◽  
Emerging Therapies ◽  
Phosphodiesterase 5 ◽  
Vacuum Erection Device

The management of erectile dysfunction has made tremendous strides over the past four decades, owing to concomitant advances in our understanding of the complex neurovascular, hormonal, and psychologic processes involved in penile erectile. The field has transitioned from predominantly psychotherapy-based management to focused treatment modalities that have been rigorously tested for both safety and efficacy in the clinical setting. The etiology of the erectile dysfunction must first be ascertained through careful history-taking, physical examination, laboratory testing, and in select cases, imaging. Once the etiology is known, the urologist has numerous options in their armamentarium to improve symptomatology and quality of life. The use of psychotherapy, pharmacologic therapy, injectable therapy, intraurethral suppositories, topical agents, and vacuum-assist erection devices can be used as monotherapy or in combination to tailor treatment to patient needs. Future directions in erectile dysfunction management are focusing on therapies that alter the course of the disease and permanently restore erectile function, rather than simply treating the symptomatology. The continued advancements taking place in the preclinical setting demonstrate considerable promise for the treatment and ultimate cure for this disease. This review contains 6 figures, 1 table, and 50 references. Key Words: alprostadil, emerging therapies, erectile dysfunction, intracavernosal injection therapy, intraurethral suppository, medical management, papaverine, phentolamine, phosphodiesterase-5 inhibitors, vacuum erection device, vasoactive intestinal peptide

SILDENAFIL VERSUS THE VACUUM ERECTION DEVICE: PATIENT PREFERENCE

2001 ◽  
Vol 166 (5) ◽  
pp. 1779-1781 ◽  
Author(s):  
JUZA CHEN ◽  
NICOLA J. MABJEESH ◽  
ALEXANDER GREENSTEIN
Keyword(s):  
Patient Preference ◽  
Vacuum Erection Device

scholarly journals Optimal pressure in penile rehabilitation with a vacuum erection device: evidence based on a rat model

2019 ◽  
Vol 21 (5) ◽  
pp. 516 ◽  
Author(s):  
Jiu-Hong Yuan ◽  
Xing-Liang Yang ◽  
Yang Yang ◽  
Fu-Dong Fu ◽  
Chang-Jing Wu ◽  
...  
Keyword(s):  
Rat Model ◽  
Evidence Based ◽  
Vacuum Erection Device ◽  
Penile Rehabilitation

A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy

2007 ◽  
Vol 100 (4) ◽  
pp. 858-862 ◽  
Author(s):  
Tobias S. Köhler ◽  
Renato Pedro ◽  
Kari Hendlin ◽  
William Utz ◽  
Roland Ugarte ◽  
...  
Keyword(s):  
Pilot Study ◽  
Radical Retropubic Prostatectomy ◽  
Retropubic Prostatectomy ◽  
Early Use ◽  
Vacuum Erection Device

Vacuum erection device in treatment of organic erectile dysfunction and penile vascular differences between patients with DM type I and DM type II

2016 ◽  
Vol 20 (1) ◽  
pp. 49-53 ◽  
Author(s):  
Bogdan Pajovic ◽  
Antonio Dimitrovski ◽  
Nikola Fatic ◽  
Milos Malidzan ◽  
Marko Vukovic
Keyword(s):  
Erectile Dysfunction ◽  
Type I ◽  
Type Ii ◽  
Vacuum Erection Device

scholarly journals Phosphodiesterase-5 Inhibitors and Vacuum Erection Device for Penile Rehabilitation After Laparoscopic Nerve-Preserving Radical Proctectomy for Rectal Cancer: A Prospective Controlled Trial

2016 ◽  
Vol 11 (3) ◽  
pp. 641-646 ◽  
Author(s):  
Haijun Deng ◽  
Dong Liu ◽  
Xiangming Mao ◽  
Xiaoliang Lan ◽  
Hao Liu ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Erectile Function ◽  
Therapy Group ◽  
Controlled Trial ◽  
Combined Therapy ◽  
Intervention Group ◽  
Phosphodiesterase Type 5 Inhibitors ◽  
The Mean ◽  
Vacuum Erection Device ◽  
Penile Rehabilitation

The current study sought to clarify the role of phosphodiesterase type 5 inhibitors (PDE-5i) and a vacuum erection device (VED) in penile rehabilitation after laparoscopic nerve-preserving radical proctectomy (LNRP) for rectal cancer. Participants were assigned to one of the following arms—no-intervention, nightly use of sildenafil 25 mg for 3 months after surgery, or concurrent use of nightly sildenafil 25 mg/day for 3 months and a vacuum erection device (VED) 10 to 15 minutes/day for 3 months—in a nonrandomized fashion. All participants had a follow-up of over 12 months prospectively, and patients had baseline, 3-, 6-, and 12-month assessment based on the International Index of Erectile Function–5 (IIEF-5). Seventy-one cases were included in final analyses. In the no-intervention group, the mean baseline IIEF-5 score of 21.9 decreased rapidly to 5.0 at 3 months ( p < .001), 9.2 at 6 months ( p < .001), and stayed at 10.9 at 12 months ( p < .001). In the single therapy group, the mean baseline IIEF-5 score of 22.4 decreased dramatically to 9.0 at 3 months ( p < .001), 14.9 at 6 months ( p = .005), and stayed at 15.1 at 12 months ( p = .005). In the combined therapy group, the mean baseline IIEF-5 score of 23.0 decreased slightly to 15.0 at 3 months ( p = .005), 18.0 at 6 months ( p = .038), and maintained at 18.7 at 12 months ( p = .163). Findings suggested an over 50% decline in the quality of erection function of the patients after LNRP. The early use of PDE-5i alone or combined use of PDE-5i and VED after LNRP maintained erectile function at 12 months.

Sign in / Sign up

Export Citation Format

Share Document